secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001723128-24-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal beats Q2 estimates, raises FY guidance; FDA approves CREXONT for Parkinson's
--------------------------------------------------------------------------------

- Q2 net revenue $702M (+17% YoY); GAAP net income $6M ($0.02 diluted EPS).
- Adjusted EBITDA $162M (+11% YoY); adjusted diluted EPS $0.16 vs $0.19 prior year.
- Raising full-year 2024 guidance on broad-based growth across all segments.
- FDA approved CREXONT (carbidopa/levodopa) for Parkinson's disease; launch expected September 2024.
- Specialty revenue +7%, Generics +14% (driven by biosimilars), AvKARE +33%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000030/0001723128-24-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312824000030/amrx-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001723128-24-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer